Telix主办一场2026年3月2日的网络研讨会, 介绍PSMA-PET/CT前列腺癌的进展, Telix hosts a March 2, 2026, webinar on PSMA-PET/CT advances for prostate cancer, featuring physicians and highlighting its radiopharmaceutical development.

Telix制药公司正在主办一场2026年3月2日的网络研讨会,邀请医学专家讨论医生对前列腺癌PSMA-PET/CT成像进展的看法。 Telix Pharmaceuticals is hosting a March 2, 2026, webinar featuring medical experts discussing physician perspectives on PSMA-PET/CT imaging advancements for prostate cancer. 这个活动向投资者和公众开放,强调Telix开发肿瘤学和罕见疾病的放射药物的全球努力。 The event, open to investors and the public, highlights Telix’s global efforts in developing radiopharmaceuticals for oncology and rare diseases. 在ASX和Nasdaq上市的公司警告说,公告包括具有临床试验结果、监管批准和市场条件等风险的前瞻性声明。 The company, listed on ASX and Nasdaq, warns that the announcement includes forward-looking statements subject to risks like clinical trial results, regulatory approvals, and market conditions.